Purinergic and pyrimidinergic receptors as potential drug targets

Biochemical Pharmacology

Volumn 59, Issue 10, 2000, Pages 1173-1185

  Williams, Michael ^a   Jarvis, Michael F ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Heptahelical receptors; Ligand gated ion channels; Purines; Receptors

Indexed keywords

2 AMINO 4,5 DIMETHYL 3 (3 TRIFLUOROMETHYLBENZOYL)THIOPHENE; 4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 6 OXO 3 (2 PHENYLPYRAZOLO[1,5 A]PYRIDIN 3 YL) 1(6H) PYRIDAZINEBUTYRIC ACID; 8 (3,4 DIMETHOXYSTYRYL) 7 METHYL 1,3 DIPROPYLXANTHINE; ADENOSINE; ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE DERIVATIVE; ADENOSINE RECEPTOR; ADENOSINE TRIPHOSPHATE DERIVATIVE; ENPROFYLLINE; ION CHANNEL; NAXIFYLLINE; PURINE P2 RECEPTOR; PURINE P2Y RECEPTOR; PURINE RECEPTOR; PURINERGIC RECEPTOR STIMULATING AGENT;

DEGENERATIVE DISEASE; DIABETES MELLITUS; DRUG STRUCTURE; DRUG TARGETING; EPILEPSY; HUMAN; INFLAMMATION; NEUROMODULATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SLEEP; UROLOGY;

EID: 0034658221     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(99)00341-X     Document Type: Article

References (109)

1. Ralevic V., Burnstock G. Receptors for purines and pyrimidines. Pharmacol Rev. 50:1998;413-492.
2. King B.F., Townsend-Nicholson A., Burnstock G. Metabotropic receptors for ATP and UTP Exploring the correspondence between native and recombinant nucleotide receptors . Trends Pharmacol Sci. 19:1998;506-514.
3. Edwards G., Weston A.H. The pharmacology of ATP-sensitive potassium channels. Annu Rev Pharmacol Toxicol. 33:1993;597-637.
4. th Generation of Progress, CD-ROM (Ed. Watson S). Lippincott Williams & Wilkins, Baltimore, MD, in press.
5. Ziganshin A.U., Hoyle C.H.V., Burnstock G. Ectoenzymes and metabolism of extracellular ATP. Drug Dev Res. 32:1994;134-146.
6. Zimmerman H. Extracellular purine metabolism. Drug Dev Res. 39:1996;337-352.
7. Silinsky E.M., Hirsh J.K., Searl T.J., Redman R.S., Watanabe M. Quantal ATP release from motor nerve endings and its role in neurally mediated depression. Prog Brain Res. 120:1999;145-158.
8. Brundege J.M., Diao L., Proctor W.R., Dunwiddie T.V. The role of cyclic AMP as a precursor of extracellular adenosine in the rat hippocampus. Neuropharmacology. 36:1997;1201-1210.
9. Jacobson K.A., van Rhee A.M. Development of selective purinoceptor agonist and antagonists. Jacobson K.A., Jarvis M.F. Purinergic Approaches in Experimental Therapeutics. 1997;101-128 Wiley-Liss, New York.
10. Nehlig A. Are we dependent upon coffee and caffeine? A review on human and animal data. Neurosci Biobehav Rev. 23:1999;563-576.
11. Fischer B. Therapeutic applications of ATP-(P2)-receptors agonists and antagonists. Exp Opin Ther Patents. 9:1999;385-400.
12. Williams M. Developments in P2 receptor targeted therapeutics. Prog Brain Res. 120:1999;93-106.
13. Sperlagh B., Vizi E.S. Neuronal synthesis, storage and release of ATP. Semin Neurosci. 8:1996;175-186.
14. Clifford E.E., Martin K.A., Dalal P., Thomas R., Dubyak G.R. Stage-specific expression of P2Y receptors, ecto-apyrase, and ecto-5′-nucleotidase in myeloid leukocytes. Am J Physiol. 273:(3 Pt 1):1997;C973-C987.
15. 7 receptor. Neuropharmacology. 36:1997;1277-1283.
16. Tordorov L.D., Mihaylova-Todorova S., Westfall T.D., Sneddon P., Kennedy C., Bjur R.A., Westfall D.P. Neuronal release of soluble nucleotidases and their role in neurotransmitter inactivation. Nature. 387:1997;76-79.
17. Communi D., Robaye B., Janssens R., Parmentier M., Boeynaems J.-M. Receptors responsive to extracellular uracil nucleotides. Drug Dev Res. 45:1998;130-135.
18. Connolly G.P., Duley J.A. Uridine and its nucleotides Biological actions, therapeutic potentials . Trends Pharmacol Sci. 20:1999;218-225.
19. Nieber K., Eschke D., Brand A. Brain hypoxia Effects of ATP and adenosine . Prog Brain Res. 120:1999;287-300.
20. Prince D.A., Stevens C.F. Adenosine decreases neurotransmitter release at central synapses. Proc Natl Acad Sci USA. 89:1992;8586-8590.
21. Yoon K.W., Rothman S.M. Adenosine inhibits excitatory but not inhibitory synaptic transmission in the hippocampus. J Neurosci. 11:1991;1375-1380.
22. Linden J. Allosteric enhancement of adenosine receptors. Jacobson K.A., Jarvis M.F. Purinergic Approaches in Experimental Therapeutics. 1997;85-97 Wiley-Liss, New York.
23. 2B receptors. Pharmacol Rev. 49:1997;381-402.
24. 2B receptors. Drug Dev Res. 47:1999;178-188.
25. 3 adenosine receptors Protective vs. damaging effects identified using novel agonists and antagonists . Drug Dev Res. 45:1998;113-124.
26. 3 receptors form stable trimers A novel structural motif of ligand-gated ion channels . EMBO J. 17:1998;3016-3028.
27. 5 receptor subunits reveals a novel ATP-gated ion channel. Mol Pharmacol. 54:1998;989-993.
28. 3 receptor subunits can account for ATP-gated currents in sensory neurons. Nature. 377:1995;432-435.
29. Dubyak G.R., Clifford E.E., Humphreys B.D., Kertsey S.B., Martin K.A. Expression of multiple ATP subtypes during the differentiation and inflammatory activation of myeloid leukocytes. Drug Dev Res. 39:1996;269-278.
30. 7 receptor A pivotal role in inflammation and immunomodulation . Drug Dev Res. 45:1998;207-213.
31. Virginio C., MacKenzie A., Rassendren F.A., North R.A., Surprenant A. Pore dilation of neuronal P2X receptor channels. Nat Neurosci. 2:1999;315-321.
32. Khakh B.S., Bao X.R., Labarca C., Lester H.A. Neuronal P2X transmitter-gated cation channels change their ion selectivity in seconds. Nat Neurosci. 2:1999;322-330.
33. Bhagwat S.S., Williams M. P2 purine and pyrimidine receptors Emerging superfamilies of G protein coupled and ligand gated ion channel receptors . Eur J Med Chem. 32:1997;183-191.
34. Kennedy C., Leff P. How should P2X receptors be classified pharmacologically? Trends Pharmacol Sci. 16:1995;168-174.
35. Bianchi B., Lynch K.J., Touma E., Niforatos W., Burgard E.C., Alexander K.M., Park H.S., Yu H., Metzger R., Kowaluk E., Jarvis M.F., van Biesen T. Pharmacological characterization of recombinant human and rat P2X receptor subtypes. Eur J Pharmacol. 376:1999;127-138.
36. 2/3 receptors. Mol Pharmacol. 53:1998;969-973.
37. 1 receptors. J Med Chem. 41:1998;183-190.
38. 2T receptor A novel approach to antithrombotic therapy . J Med Chem. 42:1999;213-220.
39. Gargett C.E., Wiley J.S. The isoquinoline derivative KN-62, a potent antagonist of the P2Z receptor of human lymphocytes. Br J Pharmacol. 120:1997;1483-1490.
40. 7 nucleotide receptor High selectivity for the human versus rat receptor homologues . Mol Pharmacol. 54:1998;22-32.
41. Kowaluk E.A., Bhagwat S.S., Jarvis M.F. Adenosine kinase inhibitors. Curr Pharm Des. 4:1998;403-416.
42. Ijzermann A.P., van der Wenden N.M. Modulators of adenosine uptake, release, and inactivation. Jacobson K.A., Jarvis M.F. Purinergic Approaches in Experimental Therapeutics. 1997;129-148 Wiley-Liss, New York.
43. 2A antagonists A novel antiparkinson agent that does not provoke dyskinesia in parkinsonian monkeys . Ann Neurol. 43:1998;507-513.
44. 1 receptor antagonist with potent diuretic activity . J Med Chem. 42:1999;779-783.
45. 1 adenosine receptor antagonist, in congestive heart failure. Drug Dev Res. 45:1998;166-171.
46. Donaldson S.H., Boucher R.C. Therapeutic applications for nucleotides in lung disease. Turner J.T., Weisman G.A., Fedan J.S. The P2 Nucleotide Receptors. 1998;413-426 Humana Press, Totowa, NJ.
47. Knutsen L.J.S., Murray T.F. Adenosine and ATP in epilepsy. Jacobson K.A., Jarvis M.F. Purinergic Approaches in Experimental Therapeutics. 1997;423-447 Wiley-Liss, New York.
48. During M.J., Spencer D.D. Adenosine A potential mediator of seizure arrest and postictal refractoriness . Anal Neurol. 32:1992;618-624.
49. Zhang G., Franklin P.H., Murray T.F. Manipulation of endogenous adenosine in the rat piriform cortex modulates seizure susceptibility. J Pharmacol Exp Ther. 264:1993;1415-1424.
50. Wiesner J.B., Ugarkar B.G., Castellino A.J., Barankiewicz J., Dumas D.P., Gruber H.E., Foster A.C., Erion M.D. Adenosine kinase inhibitors as a novel approach to anticonvulsant therapy. J Pharmacol Exp Ther. 289:1999;1669-1677.
51. Housley G.D., Greenwood D., Bennett T., Ryan A.F. Identification of a short form of the P2xR1-purinoceptor subunit produced by alternative splicing in the pituitary and cochlea. Biochem Biophys Res Commun. 212:1995;501-508.
52. Thorne P.R., Housley G.D. Purinergic signalling in sensory systems. Semin Neurosci. 8:1996;233-246.
53. Kujawa S.G., Erosteguli C., Fallon M., Christ J., Bobin R.P. Effects of adenosine 5′-triphosphate and related agonists on cochlear function. Hear Res. 76:1984;87-100.
54. Ford M.S., Nie Z., Whitworth C., Rybak L.P., Ramkumar V. Up-regulation of adenosine receptors in the cochlea by cisplatin. Hear Res. 111:1997;143-152.
55. Hu B.H., Zheng X.Y., McFadden S.L., Kopke R.D., Henderson D. R-Phenylisopropyladenosine attenuates noise-induced hearing loss in the chinchilla. Hear Res. 113:1997;198-206.
56. Ferré S., Fredholm B.B., Morelli M., Popoli P., Fuxe K. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci. 20:1997;482-487.
57. 2A receptor. Nature. 388:1997;674-678.
58. 2A receptor antagonists as new agents for the treatment of Parkinson's disease. Trends Pharmacol Sci. 18:1997;338-344.
59. Martin G.E., Rossi D., Jarvis M.F. Adenosine agonists reduce conditioned avoidance responding in the rat. Pharmacol Biochem Behav. 45:1993;951-958.
60. Burnstock G. A unifying purinergic hypothesis for the initiation of pain. Lancet. 347:1996;1604-1605.
61. Dubyak G.R., El Moatassim C. Signal transduction via P2-purinergic receptors for extracellular ATP and other nucleotides. Am J Physiol. 265:1993;C577-C606.
62. Bland-Ward P.A., Humphrey P.P.A. Acute nociception mediated by hindpaw P2X receptor activation in the rat. Br J Pharmacol. 122:1997;365-371.
63. 2-purinoceptor antagonists in rats. Brain Res. 666:1994;182-188.
64. Hamilton S., Wade A., McMahon S.B. The effects of inflammation and inflammatory mediators on nociceptive behavior induced by ATP analogues in the rat. Br J Pharmacol. 126:1999;326-332.
65. 2X receptor. Eur J Pharmacol. 330:1997;115-121.
66. 3 receptor subunits in rat and monkey sensory neurons and their central terminals. Neuropharmacology. 36:1997;1229-1242.
67. 3 purinoceptor and IB4 binding sites . Eur J Neurosci. 11:1999;946-958.
68. 2+ by speeding recovery of P2X receptors from desensitization. J Neurosci. 18:1998;9238-9244.
69. 3 receptors in normal and neuropathic rats. Pharmacologist. 29:1996;56.
70. Chen C.C., Akoplan A.N., Sivllotti L., Colquhoun D., Burnstock G., Wood J. A P2X purinoceptor expressed by a subset of sensory neurons. Nature. 377:1995;428-431.
71. Sawynok J. Purines in pain management. Curr Opin CPNS Invest Drugs. 1:1999;27-38.
72. Lynch J.J., Jarvis M.F., Kowaluk E.A. An adenosine kinase inhibitor attenuates tactile allodynia in a rat model of diabetic neuropathic pain. Eur J Pharmacol. 364:1999;141-146.
73. Lee Y.W., Yaksh T.L. Pharmacology of the spinal adenosine receptor which mediates the antilipolytic action of intrathecal adenosine agonists. J Pharmacol Exp Ther. 277:1997;1642-1648.
74. 1-selective adenosine agonist abolishes allodynia elicited by vibration and touch after intrathecal injection. Anesth Analg. 80:1995;844-847.
75. Delander G.E., Wahl J.J. Behavior induced by putative nociceptive neurotransmitters is inhibited by adenosine or adenosine analogs coadministered intrathecally. J Pharmacol Exp Ther. 246:1988;565-570.
76. Segerdahl M., Sollevi A. Adenosine and pain relief A clinical overview . Drug Dev Res. 45:1998;151-158.
77. Ekbom A., Sergerdahl M., Sollevi A. Adenosine but not ketamine or morphine increases the cutaneous heat pain threshold in healthy volunteers. Acta Anesth Scand. 39:1995;717-722.
78. Belfrage M., Sollevi A., Sergerdahl M., Sjolund K.-F., Hansson P. Systemic adenosine infusion alleviates spontaneous and stimulus evoked pain in patients with peripheral neuropathic pain. Anesth Analg. 81:1995;713-717.
79. Fukunaga A.F. Purines in anesthesia. Jacobson K.A., Jarvis M.F. Purinergic Approaches in Experimental Therapeutics. 1997;471-494 Wiley-Liss, New York.
80. Wang B., Tang J., White P.F., Foster A.C., Grettenberger H.M., Kopcho J., Wender R.H. The effect of GP683, an adenosine kinase inhibitor, on the desflurane anesthetic requirement in dogs. Anesth Analg. 85:1997;675-680.
81. Firestein G.S. Anti-inflammatory effects of adenosine kinase inhibitors in acute and chronic inflammation. Drug Dev Res. 39:1996;371-376.
82. Firestein G.S., Paine M.M., Boyle D.L. Mechanisms of methotrexate action in rheumatoid arthritis. Selective decrease in synovial collagenase gene expression. Arthritis Rheum. 37:1994;193-200.
83. Cronstein B.N., Montesinos M.C., Weissman G. Salicylates and sulfasalazine, but not glucocorticoids, inhibit leukocyte accumulation by an adenosine-dependent mechanism that is independent of prostaglandin synthesis and p105 of NFκB. Proc Natl Acad Sci USA. 96:1999;6377-6381.
84. Ziganshina L.E., Ziganshin A.U., Hoyle C.H., Burnstock G. Acute paw oedema formation induced by ATP Re-evaluation of the mechanisms involved . Inflamm Res. 45:1996;96-102.
85. Carley D., Radulovacki M. Adenosine effects in sleep apnea. Jacobson K.A., Jarvis M.F. Purinergic Approaches in Experimental Therapeutics. 1997;515-526 Wiley-Liss, New York.
86. Porkka-Heiskanen T., Strecker R.E., Thallar M., Bjorkum A.A., Greene R.W., McCarley R.W. Adenosine A mediator of the sleep-inducing effects of prolonged wakefulness . Science. 276:1997;1265-1268.
87. 2 in rats. Proc Natl Acad Sci USA. 93:1996;5980-5984.
88. Neary J.T., Rathbone M.P., Cattabeni F., Abbracchio M.P., Burnstock G. Trophic actions of extracellular nucleotides and nucleosides on glial and neuronal cells. Trends Neurosci. 19:1996;13-18.
89. Rathbone M.P., Middlemiss P.J., Gysbers J., Diamond J., Holmes M., Pertens E., Juurlink B.H., Glasky A., Ritzmann R., Glasky M., Crocker C.E., Ramirez J.J., Lorenzen A., Fein T., Schulze E., Schwabe U., Ciccarelli R., Di Iorio P., Caciagli F. Physiology and pharmacology of natural and synthetic nonadenosine-based purines in the nervous system. Drug Dev Res. 45:1998;356-372.
90. 7) receptors. Immunity. 7:1997;433-444.
91. Burnstock G., Cocks T., Crowe R., Kasakov I. Purinergic innervation of the guinea-pig urinary bladder. Br J Pharmacol. 63:1978;125-138.
92. Dean D.M., Downie J.W. Contribution of adrenergic and 'purinergic' neurotransmission to contraction in rabbit detrusor. J Pharmacol Exp Ther. 207:1978;430-437.
93. Chancellor M.B., Kaplan S.A., Blaivas J.G. The cholinergic and purinergic components of detrusor contractility in a whole rabbit bladder model. J Urol. 148:1992;906-909.
94. Pinna C., Puglis C., Burnstock G. ATP and vasoactive intestinal polypeptide relaxant responses in hamster isolated proximal urethra. Br J Pharmacol. 124:1998;1069-1074.
95. Yoshimura N., de Groat W.C. Neural control of the lower urinary tract. Int J Urol. 4:1997;111-125.
96. Hashimoto M., Kokubun S. Contribution of P2-purinoceptors to neurogenic contraction of rat urinary bladder smooth muscle. Br J Pharmacol. 115:1995;636-640.
97. Rapaport E. ATP in the treatment of cancer. Jacobson K.A., Jarvis M.F. Purinergic Approaches in Experimental Therapeutics. 1997;545-553 Wiley-Liss, New York.
98. Abraham E.H., Vos P., Kahn J., Grubman S.A., Jefferson D., Ding I., Okunieff P. Cystic fibrosis hetero- and homozygosity is associated with inhibition of breast cancer growth. Nat Med. 2:1996;593-596.
99. Loubatrieres-Mariani M., Hillaire-Buys D., Chapal J., Betrand G., Petit P. P2 purinoceptor agonists, New insulin secretagogues potentially useful in the treatment of non-insulin-dependent diabetes mellitus. Jacobson K.A., Jarvis M.F. Purinergic Approaches in Experimental Therapeutics. 1997;253-260 Wiley-Liss, New York.
100. Nichols C.G., Shyng S.-L., Nestorowicz A., Glaser B., Clement J.P. IV, Gonzalez G., Aguilar-Bryan L., Permutt M.A., Bryan J. Adenosine diphosphate is an intracellular regulator of insulin secretion. Science. 272:1996;1785-1787.
101. Fischer Y., Becker C., Loken C. Purinergic inhibition of glucose transport in cardiomyocytes. J Biol Chem. 274:1999;755-761.
102. Katchanov G., Xu J., Schulman E.S., Pelleg A. ATP-triggered reflex bronchoconstriction. Drug Dev Res. 45:1998;342-349.
103. Srinivas M., Song Y., Shryock J.C., Belardinelli L. Cardiac electrophysiological actions of adenosine. Drug Dev Res. 45:1998;420-426.
104. Liu G.-S., Downey J.M., Cohen M.V. Adenosine, ischemia and preconditioning. Jacobson K.A., Jarvis M.F. Purinergic Approaches in Experimental Therapeutics. 1997;153-172 Wiley-Liss, New York.
105. 2 receptor agonist AMP 579 in a porcine model of myocardial infarction. J Pharmacol Exp Ther. 286:1998;611-618.
106. 3 receptors Pharmacological properties, species differences and receptor functions . Trends Pharmacol Sci. 15:1994;298-306.
107. Wilcox C.S., Welch W.J., Schreiner G.F., Bellardinelli L. Natriuretic and diuretic actions of a highly selective adenosine A1 receptor antagonist. J Am Soc Nephrol. 10:1999;714-720.
108. Jackson E. Renal actions of purines. Jacobson K.A., Jarvis M.F. Purinergic Approaches in Experimental Therapeutics. 1997;217-250 Wiley-Liss, New York.
109. Delombe S., Escande D. ATP-binding cassette proteins as targets for drug discovery. Trends Pharmacol Sci. 17:1996;273-275.